Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast media presented as an injectable solution for intraarterial, intravenous use. It provides radiodensity for imaging procedures and is used in patients undergoing X‑ray, CT, and angiographic studies.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optiray (ioversol) is an iodinated contrast agent used to enhance radiographic visualization of vascular and organ structures.

- CT imaging: improves contrast between tissues for clearer diagnostic images. - Angiography: delineates blood vessels to aid in vascular assessment. - X‑ray studies: enhances visualization of anatomical details during conventional radiography.

Adverse reactions may occur following administration of ioversol. Patients should be monitored for both common and serious events.

Common Side Effects: - Warm sensation or flushing at the injection site. - Metallic taste in the mouth. - Nausea or vomiting. - Mild headache. - Transient hypotension. - Injection site pain.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Contrast‑induced nephropathy or renal impairment. - Pulmonary edema. - Cardiac arrhythmia. - Seizures. - Severe hypotension or shock.

Prior to using Optiray, clinicians should consider several safety measures.

- Renal function: assess kidney function and hydration status before administration. - Allergy history: screen for previous reactions to iodine‑containing contrast agents. - Thyroid disease: use with caution in patients with hyperthyroidism or thyroid disorders. - Pregnancy: category B; employ only when diagnostic benefit outweighs potential risk. - Concomitant nephrotoxic drugs: monitor closely if patient is receiving aminoglycosides, NSAIDs, or similar agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioversol may interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodine‑containing drugs (e.g., amiodarone): increase risk of thyroid dysfunction. - Nephrotoxic agents (e.g., aminoglycosides, high‑dose NSAIDs): heightened risk of renal injury. - Diuretics: may exacerbate volume depletion and affect renal perfusion.

Moderate Interactions (Monitor Closely): - Metformin: risk of lactic acidosis in patients with impaired renal function. - ACE inhibitors or ARBs: monitor renal function and blood pressure. - Beta‑blockers: may mask signs of hypotension after contrast administration.